Skip to content

A randomized controlled trial of the lumbar-type of HAL for the safety and efficacy in hemiplegic patients with acute stroke

A randomized controlled trial of the lumbar-type of the Wearable Cyborg HAL (Hybrid Assistive Limb) for the safety and efficacy in hemiplegic patients with acute stroke

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs032230039
Enrollment
44
Registered
2023-04-17
Start date
2023-11-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral infarction and cerebral hemorrhage patients with hemiplegia and sit-to-stand disorder Cerebral infarction, Cerebral hemorrhage

Interventions

In the HAL group, an intervention program using a lumbar-type of HAL is performed for 20 minutes once a day for a total of 9 times. In the control group, an intervention program without a lumbar-type
Intervention program with/without a lumbar-type of wearable cyborg HAL

Sponsors

Matsumaru Yuji
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients who can agree to the document by themselves. (However, if writing is difficult, set a writer) 2) Patients aged 16 years or older. (If you are under 18 years old, in addition to the signature of the person himself/herself, a signature by a parent or guardian is also needed) 3) Patients within 2 to 21 days after onset. (The day of stroke onset is treated as day 0) 4) Patients with Functional Ambulation Category (FAC) from 0 to 2. 5) Patients with FAC of 4 or more before onset. 6) Patients who can wear the lumbar-type of HAL. (Height is assumed to be 150 cm-190 cm, but the condition of use is not height, but for patients whose, body size such as thigh length, lower leg length, waist width, etc. fits)

Exclusion criteria

Exclusion criteria: 1) Patients who have difficulty performing voluntary limb movements according to instructions due to consciousness disorder or cognitive decline. 2) Patients who have difficulty in training joint exercises or wearing lumbar-type of HAL due to complications such as heart disease and musculoskeletal system, which are problems during exercise. 3) Patients who cannot attach lumbar-type of HAL bio-electrode due to skin diseases. 4) Patients who participated in other interventional studies within 12 weeks of the start of this clinical study. 5) Patient who is judged to be medically unstable by the principal investigator or member doctors after comprehensively considering physical findings, examination findings, etc.

Design outcomes

Primary

MeasureTime frame
The amount of change from baseline to the end of the intervention in the Berg Balance Scale (BBS)

Secondary

MeasureTime frame
The amount of change from baseline to the end of the intervention in the Fugl-Meyer assessment of the lower limbs The amount of change from baseline to the end of the intervention in the Brunnstrom Recovery Stage of the upper, finger, and lower limbs The amount of change from baseline to the end of the intervention in the isometric knee extensor muscle strength (both sides) The amount of change from baseline to the end of the intervention in the Trunk Impairment Scale The amount of change from baseline to the end of the intervention in the Functional Ambulation Category The amount of change from baseline to the end of the intervention in the 30-second chair stand test The amount of change from baseline to the end of the intervention in the Functional Independence Measure (motor, cognitive, and total score) The amount of change from baseline to the end of the intervention in the modified Rankin Scale (Japanese version). However, the change in the score will be evaluated by scoring the grade, with grade 0 being 6 points and grade 6 being 0 points. Occurrence of diseases, etc., the occurrence of defects in test equipment The score prior to the intervention on the Mini-Mental State Examination (only pre-assessment) The amount of change from baseline to the end of the intervention in the motion analysis of stand-up and walking (including gait speed, steps length, and cadence), muscle activity, motion test using an acceleration sensor, brain activity, a test of brain function (functional MRI, transcranial magnetic stimulation) (only possible case)

Contacts

Public ContactAiki Marushima

University of Tsukuba Hospital

aiki.marushima@md.tsukuba.ac.jp+81-29-853-3220

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026